BB Biotech (BION) AI Stock Analysis

• Market Cap: CHF1.58B
• Dividend Yield: 6.24%
• Average Volume (3M): 99.54K
• Price to Earnings (P/E): 20.8
• Beta (1Y): 1.10
• Revenue Growth: 1786.54%
• EPS Growth: -238.40%
• Country: CH
• Employees: 10
• Sector: Healthcare
• Sector Strength: 39
• Industry: Biotechnology
• EPS (TTM): -7.76
• Shares Outstanding: 55,400,000
• 10 Day Avg. Volume: 76,824
• 30 Day Avg. Volume: 99,536
• PEG Ratio: -0.34
• Price to Book (P/B): 0.90
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 13.66
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: CHF66.00
• Price Target Upside: 133.22% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

BB Biotech has shown a strong recovery with high profitability and a stable balance sheet. However, historical volatility in financial performance and bearish technical indicators present risks. The stock's attractive valuation and high dividend yield provide a buffer, but caution is advised until technical signals improve or financial performance stabilizes further.

BB Biotech Business Overview & Revenue Model

Company Description

BB Biotech (BION) is an investment company specializing in biotechnology. It primarily invests in companies that are developing transformative drugs and technologies in the healthcare sector. BB Biotech's portfolio is strategically diversified across various therapeutic areas, including oncology, neurology, and infectious diseases, with a focus on companies that have high growth potential and innovative products.

How the Company Makes Money

BB Biotech makes money through its investment activities in the biotechnology sector. The company generates revenue primarily from the appreciation of its investments in biotechnology companies. This includes capital gains realized from selling shares of companies within its portfolio at a profit. BB Biotech also earns income from dividends distributed by the companies in which it holds equity. The company's success is closely tied to the performance of its portfolio companies, which can be influenced by factors such as successful clinical trial results, regulatory approvals, and market demand for new therapies. Additionally, BB Biotech may engage in strategic partnerships or collaborations to enhance its investment opportunities and returns.

BB Biotech Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown
TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
144.42M	-199.57M	-351.23M	-396.22M	699.23M	685.24M
	Gross Profit
232.23M	-199.57M	-351.23M	-396.22M	699.23M	685.24M
	EBIT
206.27M	-29.93M	-356.02M	-404.74M	691.25M	677.50M
	EBITDA
78.12M	-201.26M	-357.29M	-402.79M	691.25M	677.50M
	Net Income Common Stockholders
125.36M	-206.61M	-357.81M	-404.81M	691.17M	677.43M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
2.82B	2.64B	1.95M	2.83M	6.82M	30.71M
	Total Assets
2.83B	2.64B	3.05B	3.64B	3.96B	3.55B
	Total Debt
344.70M	304.90M	363.00M	355.00M	63.00M	150.00M
	Net Debt
344.30M	-501.00K	361.05M	352.17M	56.18M	119.29M
	Total Liabilities
353.99M	313.94M	367.25M	355.00M	63.00M	161.59M
	Stockholders Equity
2.47B	2.32B	2.69B	3.28B	3.89B	3.39B
Cash Flow		Free Cash Flow
146.18M	218.28M	-357.81M	-94.79M	262.45M	215.02M
	Operating Cash Flow
97.09M	218.28M	-357.81M	-94.79M	262.45M	215.02M
	Investing Cash Flow
0.00	0.00	588.94M	0.00	0.00	0.00
	Financing Cash Flow
-144.09M	-220.21M	-233.27M	91.77M	-284.48M	-205.21M

BB Biotech Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 28.30
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:BION, the sentiment is Negative. The current price of 28.3 is below the 20-day moving average (MA) of 28.50, below the 50-day MA of 30.21, and below the 200-day MA of 34.32, indicating a bearish trend. The MACD of -0.22 indicates Negative momentum. The RSI at 43.76 is Neutral, neither overbought nor oversold. The STOCH value of 30.07 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CH:BION.

BB Biotech Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BSLN	72 Outperform	CHF539.22M	6.81		―	32.30%	631.04%
NWRN	66 Neutral	CHF163.68M	11.57		―	450.19%	―
BION	60 Neutral	CHF1.58B	20.77	-19.26%	6.24%	1786.54%	-238.40%
KURN	57 Neutral	$875.93M	―	-6.44%	―	125.11%	69.27%
IDIA	55 Neutral	CHF294.42M	―		―	11.61%	-356.20%
Sector *	52 Neutral	$5.14B	3.39	-43.55%	2.83%	16.49%	-0.19%
SANN	47 Neutral	$129.67M	2.58	-93.91%	―	-62.17%	-166.33%

BB Biotech Corporate Events

BB Biotech AG Reports Q1 2025 Loss Amidst Market Challenges

BB Biotech AG has released its interim report for the first quarter of 2025, revealing a loss of CHF 241 million, a significant shift from the CHF 260 million profit recorded in the same period last year. This loss reflects the stock price development of the companies within its investment portfolio, indicating potential challenges in the biotech investment landscape.

BB Biotech Refines Portfolio Amid Market Challenges in Q1 2025

BB Biotech faced a challenging first quarter in 2025 due to market volatility and political uncertainties, resulting in a net loss of CHF 241 million. Despite these challenges, the company sharpened its portfolio focus by investing in high-quality biotech firms and reducing its number of holdings, while achieving regulatory milestones with several portfolio companies. The company remains committed to its long-term strategy of investing in groundbreaking therapies, with a focus on companies that have strong pricing power and lean cost structures.

BB Biotech AG Approves Dividend and Re-elects Board Members

BB Biotech AG’s General Meeting has approved all proposals from the Board of Directors, including a dividend of CHF 1.80 per share, to be paid on March 25, 2025. The re-election of the board members signifies stability and continuity in the company’s leadership, which is expected to positively impact its strategic investment decisions and maintain its strong position in the biotech investment sector.